Clinical Trials Directory

Trials / Terminated

TerminatedNCT05070130

OpSens PRIME CLASS

OpSens dPR for Physiological Assessment of Intermediate Coronary Lesions in Aortic Stenosis

Status
Terminated
Phase
Study type
Observational
Enrollment
32 (actual)
Sponsor
Opsens, Inc. · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

In this study it is aimed to determine the diagnostic value of physiological measurements in the presence of aortic stenosis, and whether these are more accurate than angiographic assessment. Post-TAVR FFR will be taken as the reference for predicting ischemic lesions, and angiography and physiology - FFR and diastolic pressure ratio (dPR) - will be performed immediately before and after TAVR, in an all-comer multicentric observational study.

Detailed description

This is a post-marketing, prospective, observational, single arm, multi-center, single country study in Subjects who have severe symptomatic aortic stenosis with a formal indication for TAVR, and one or more intermediate coronary lesions in a relevant coronary artery (\>2mm). This study aims to assess if OpSens non-hyperemic dPR (based on a proprietary algorithm) and/or OpSens FFR are suitable methods for the physiological assessment and prediction of ischemic coronary lesions in Subjects with aortic stenosis who are considered for TAVR. This will be done by comparing pre-TAVR measurements of angiography, dPR and FFR and placing them against the post-TAVR FFR, which is considered as the gold standard. Also the post TAVR dPR will be compared with post-TAVR FFR. A maximum of 137 subjects will be enrolled in 5 to 10 sites in Spain to obtain the required minimum of 137 lesions (see section 11.2 Sample Size Determination) The main hypothesis is that the specificity to predict ischemic lesions in TAVR candidates based on a pre-TAVR dPR ≤ 0.89 is superior compared to the specificity based on angiography alone (both QCA and visual assessment of the stenosis \>50%), taking the post-TAVR FFR value of ≤ 0.80 as a reference for positive lesions. The pressure guidewire used to measure dPR and FFR during diagnostic angiography is the commercially available (CE-marketed) OptoWire family of pressure guidewires from OpSens Inc.

Conditions

Interventions

TypeNameDescription
DEVICEdPR and FFROpSens non-hyperemic dPR and/or OpSens FFR

Timeline

Start date
2022-09-19
Primary completion
2023-03-15
Completion
2023-04-04
First posted
2021-10-07
Last updated
2023-04-27

Locations

5 sites across 1 country: Spain

Source: ClinicalTrials.gov record NCT05070130. Inclusion in this directory is not an endorsement.